LOS ANGELES, July 25, 2023 (GLOBE NEWSWIRE) Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. (“Nexcella”, “Company”, “We” or “Us”), today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical
Tumor shrinkage was observed in 3 out of 4 patients; 1 out of 4 experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory.
Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All
Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Supports planned expansion of its ongoing NEXICART-1 NXC-201 CAR-T clinical trial to the U.S.LOS ANGELES, July 10, 2023 Nexcella, Inc., a subsidiary of Immix Biopharma, Inc. , today announced.